ANRO — Alto Neuroscience, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1999480 ·
Last close
$24.91
Market Cap
$999.16M
52W High
$37.48
52W Low
$12.51
ADV30
647,338
Next earnings
2026-11-10
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -27,225,000 -25,124,000 326,505,000 319,344,000 29,975,000
Jun 2026 0 — -29,129,000 -27,638,000 254,066,000 243,733,000 34,817,000
Mar 2026 0 — -27,138,000 -26,237,000 276,259,000 263,762,000 32,890,000
Dec 2025 0 — -17,055,000 -16,182,000 184,689,000 176,484,000 33,547,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-79,123,000
Investing CF
$-556,000
Financing CF
$261,218,000
CapEx
$-580,000
Dividends Paid
—
Buybacks
$-5,774,000
EPS Diluted TTM
$-2.51
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-280,633,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-93,107,000
Pretax Income TTM
$-95,181,000
Interest Exp TTM
$2,074,000
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -66,364,000 -63,238,000 184,689,000 33,547,000 151,142,000 -51,769,000
Dec 2024 0 -68,610,000 -61,431,000 177,542,000 26,082,000 151,460,000 -47,424,000
Dec 2023 0 -37,809,000 -36,305,000 86,628,000 158,300,000 -71,672,000 -33,448,000
Dec 2022 0 -27,455,000 -27,710,000 50,854,000 89,260,000 -38,406,000 -20,394,000

TTM Snapshot

Revenues TTM
$6,766,000
NetIncome TTM
$-84,238,000
OpCashFlow TTM
—
Assets (Latest)
$254,066,000
Forward EPS
$-2.99

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $25.91 · call volume: 50 · put volume: 156
Expected Move to 2027-01-15: ±$7.70 (29.72%) — implied range $18.21 – $33.61 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CYRX Cryoport, Inc. $999.81M $19.74 —
OMER OMEROS CORP $1.01B $13.92 —
SVRA Savara Inc $988.39M $4.48 —
JBIO Jade Biosciences, Inc. $979.40M $15.40 —
MTRI InMed Pharmaceuticals Inc. $1.02B $17.50 —

News headlines (Yahoo Finance, 1h cache)

Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?
2026-11-19 01:12 · Yahoo
Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
2026-11-16 16:00 · Yahoo
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
2026-11-16 13:55 · Yahoo
Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts
2026-11-11 20:44 · Yahoo
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 21:05 · Yahoo
Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value
2026-11-10 08:10 · Yahoo
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-11-03 13:03 · Yahoo
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
2026-08-27 20:05 · Yahoo
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
2026-08-16 20:07 · Yahoo
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
2026-08-16 08:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.